TW201808904A - Process for preparing boscalid - Google Patents
Process for preparing boscalid Download PDFInfo
- Publication number
- TW201808904A TW201808904A TW106126004A TW106126004A TW201808904A TW 201808904 A TW201808904 A TW 201808904A TW 106126004 A TW106126004 A TW 106126004A TW 106126004 A TW106126004 A TW 106126004A TW 201808904 A TW201808904 A TW 201808904A
- Authority
- TW
- Taiwan
- Prior art keywords
- becquerel
- item
- patent application
- elevated temperature
- solution
- Prior art date
Links
- WYEMLYFITZORAB-UHFFFAOYSA-N boscalid Chemical compound C1=CC(Cl)=CC=C1C1=CC=CC=C1NC(=O)C1=CC=CN=C1Cl WYEMLYFITZORAB-UHFFFAOYSA-N 0.000 title abstract description 6
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 239000005740 Boscalid Substances 0.000 title abstract 5
- 229940118790 boscalid Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 claims abstract description 54
- 230000004048 modification Effects 0.000 claims abstract description 43
- 238000012986 modification Methods 0.000 claims abstract description 43
- 239000003960 organic solvent Substances 0.000 claims abstract description 24
- 239000007787 solid Substances 0.000 claims abstract description 23
- 238000010438 heat treatment Methods 0.000 claims abstract description 8
- 230000001376 precipitating effect Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 31
- 238000001556 precipitation Methods 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 16
- 239000008096 xylene Substances 0.000 claims description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 6
- 150000002170 ethers Chemical class 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 230000000855 fungicidal effect Effects 0.000 claims description 5
- 239000003495 polar organic solvent Substances 0.000 claims description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical group 0.000 claims description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 3
- 239000003849 aromatic solvent Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 claims description 3
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 claims description 2
- ZPQAKYPOZRXKFA-UHFFFAOYSA-N 6-Undecanone Chemical compound CCCCCC(=O)CCCCC ZPQAKYPOZRXKFA-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 125000002723 alicyclic group Chemical group 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 125000000532 dioxanyl group Chemical group 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000000243 solution Substances 0.000 description 34
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- -1 C 5 alcohols Chemical class 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 241000218158 Clematis Species 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- JPBWZIPCMDZOPM-UHFFFAOYSA-N 2-(4-chlorophenyl)aniline Chemical compound NC1=CC=CC=C1C1=CC=C(Cl)C=C1 JPBWZIPCMDZOPM-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000012265 solid product Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- IBRSSZOHCGUTHI-UHFFFAOYSA-N 2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Cl IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WLLGXSLBOPFWQV-UHFFFAOYSA-N MGK 264 Chemical class C1=CC2CC1C1C2C(=O)N(CC(CC)CCCC)C1=O WLLGXSLBOPFWQV-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- XYQRVKIIVPVMCF-UHFFFAOYSA-N NC1=CC=CC=C1.OC(=O)C1=CC=CN=C1 Chemical compound NC1=CC=CC=C1.OC(=O)C1=CC=CN=C1 XYQRVKIIVPVMCF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical class C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000004562 water dispersible granule Substances 0.000 description 1
- 239000004565 water dispersible tablet Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
本發明關於製備白克列之方法,特別是關於製備白克列的特定結晶形式之方法。 The present invention relates to a method for preparing becquerel, in particular to a method for preparing a specific crystalline form of becquerel.
具有通用名稱為白克列的化合物2-氯-N-(4'氯[1,1'聯苯基]-2-基)-3-吡啶甲醯胺具有結構式I:
白克列是羧醯胺基團之殺真菌劑,並作為琥珀酸脫氫酶抑制劑(SDHI),即線粒體的呼吸抑制劑。這種類別的羧醯亞胺化合物和該等化合物之活性首次描述於US 4,001,416和US 5,330,995中。 Becogli is a fungicide of carboxyamide group and acts as a succinate dehydrogenase inhibitor (SDHI), a respiratory inhibitor of mitochondria. Carboximide compounds of this class and their activities are first described in US 4,001,416 and US 5,330,995.
白克列作為殺真菌劑是有活性的,並且其現在以一系列用於處理真菌感染及其所產生疾病的配製物為可商購的。 Buclacre is active as a fungicide, and it is now commercially available as a series of formulations for the treatment of fungal infections and the resulting diseases.
US 7,087,239涉及菸鹼酸苯胺和/或苯甲醯苯胺衍生物的結晶水合物。US 7,087,239中具體例示白克列的水合物的合成和回收。藉由首先製備白克列的無水物來獲得該水合物,該白克列的無水物在合成過程結束時作為熱二甲苯中的溶液獲得。冷卻後,從該溶液中結晶出白克列並且 在烘箱中於真空下乾燥。該無水物被指出具有以下物理特性: US 7,087,239 relates to crystalline hydrates of nicotinic acid aniline and / or benzanilide derivatives. US 7,087,239 specifically exemplifies the synthesis and recovery of the hydrate of becquerel. The hydrate is obtained by first preparing the anhydrous product of becquerel, which is obtained as a solution in hot xylene at the end of the synthesis process. After cooling, white clematis crystallized from the solution and dried in an oven under vacuum. The anhydrous substance is pointed out to have the following physical properties:
分子量[g/mol]:343.2 Molecular weight [g / mol]: 343.2
熔點[℃](DSC):145.2 Melting point [℃] (DSC): 145.2
密度[g/mol]:1.42 Density [g / mol]: 1.42
X射線反射(2θ度):18;22.5;9.5;6 X-ray reflection (2θ degrees): 18; 22.5; 9.5; 6
Cu-Kα Cu-Kα
IR吸收[cm-1]:1650 IR absorption [cm -1 ]: 1650
含水量[%]:<1 Water content [%]: <1
US 7,087,239揭露可以藉由在40℃下在溶劑中將該無水物溶解到四氫呋喃(THF)中並將所得溶液添加到水中而形成該水合物。藉由過濾從所得混合物中分離出沈澱並乾燥,以產出白克列的單水合物。US 7,087,239中揭露的白克列無水物的結晶變體在本文中被稱作白克列的結晶變體I。 US 7,087,239 discloses that the hydrate can be formed by dissolving the anhydrous substance in tetrahydrofuran (THF) in a solvent at 40 ° C and adding the resulting solution to water. The precipitate was separated from the resulting mixture by filtration and dried to produce the white hydrate monohydrate. The crystalline modification of becquerel anhydrate disclosed in US 7,087,239 is referred to herein as crystalline modification I of becquerel.
US 7,241,896涉及用於生產2-鹵素-吡啶-甲醯胺之方法,其揭露和例示白克列的製備。在該等實例中,藉由2-氯-3-菸鹼基鹵化物II與2-(4-氯苯基)苯胺在溶劑系統(具體地是二甲苯)中進行反應來合成白克列。用碳酸鈉溶液萃取後,藉由穩步冷卻有機溶液來結晶白克列。 US 7,241,896 relates to a method for the production of 2-halogen-pyridine-carboxamide, which discloses and exemplifies the preparation of beclomethol. In these examples, becquerel was synthesized by reacting 2-chloro-3-nicotinyl halide II with 2- (4-chlorophenyl) aniline in a solvent system (specifically xylene). After extraction with sodium carbonate solution, the white clematis was crystallized by cooling the organic solution steadily.
我們已經發現難以在水中研磨那從US 7,087,239中揭露的白克列無水物的結晶變體。因此,直接將白克列的結晶變體配製成需要研磨和/或磨細過程的所需配製物不是一項簡單的任務。這樣的配製物是,例如粒劑,膠囊粒劑,片劑,水分散性粒劑,水分散性片劑,可溼性粉劑或用於種子處理的可溼性粉劑,粉劑配製物,以及其中活性化合物以分散形 式存在的配製物,例如水懸劑,水分散性油懸劑,濃懸乳劑或種子處理用水懸劑。在配製成水懸劑之前,需要水合白克列的結晶變體。 We have found that it is difficult to grind the crystalline variant of Becquerel Anhydrous disclosed in US 7,087,239 in water. Therefore, it is not a simple task to directly formulate the crystalline variant of Becquerel into the desired formulation that requires grinding and / or grinding processes. Such formulations are, for example, granules, capsule granules, tablets, water-dispersible granules, water-dispersible tablets, wettable powders or wettable powders for seed treatment, powder formulations, and Formulations in which the active compound is present in dispersed form, such as water suspensions, water-dispersible oil suspensions, concentrated suspension emulsions or water suspensions for seed treatment. Before being formulated into an aqueous suspension, crystalline variants of becquerel need to be hydrated.
US 7,501,384揭露白克列無水物的所謂新穎結晶變體。US 7,501,384中揭露的結晶變體在本文中被稱作白克列的結晶變體II。在US 7,501,384中提出,白克列的結晶變體II更適合用於製造各種配製物,否則該等配製物需要長時間的研磨/磨細過程。 US 7,501,384 discloses the so-called novel crystalline variants of Becquerel anhydrous. The crystalline modification disclosed in US 7,501,384 is referred to herein as the crystalline modification II of Becquerel. In US 7,501,384, it is proposed that the crystalline modification II of Becquerel is more suitable for manufacturing various formulations, otherwise these formulations require a long grinding / grinding process.
US 7,501,384描述了白克列的結晶變體II可以藉由如下方法製備,該方法包括:a)將白克列的結晶變體I的無水物溶解在極性有機溶劑或芳香族烴中;並且b)藉由冷卻該溶劑來沈澱白克列的結晶變體II的無水物。 US 7,501,384 describes that the crystalline modification II of becquerel can be prepared by a method comprising: a) dissolving the anhydrous substance of the crystalline modification I of becquerel in a polar organic solvent or aromatic hydrocarbon; and b ) By cooling the solvent, the anhydrous substance of the crystalline modification II of becquerel was precipitated.
US 7,501,384中揭露的製備白克列的結晶變體II之替代方法包括:a)將白克列的結晶變體I加熱至150℃以上直至熔化;並且b)藉由添加白克列的結晶變體II的晶種來冷卻該融化物。 An alternative method for preparing crystalline modification II of becquerel disclosed in US 7,501,384 includes: a) heating crystalline modification I of becquerel above 150 ° C until melting; and b) crystalline modification by adding becquerel Seed crystals of body II to cool the melt.
US 7,501,384描述了白克列的結晶變體II,其具有以下性質: US 7,501,384 describes the crystalline modification II of becquerel, which has the following properties:
分子量[g/mol]:342 Molecular weight [g / mol]: 342
熔點[℃](DSC):147.2 Melting point [℃] (DSC): 147.2
熔化熱[J/g](DSC):106 Heat of fusion [J / g] (DSC): 106
密度[g/cm3]:1.457 Density [g / cm 3 ]: 1.457
特徵IR帶[cm-1]:868,917,1675 Characteristic IR band [cm -1 ]: 868, 917, 1675
使用西門子的單晶繞射儀從白克列的結晶變體II的晶體學研究中獲得的關鍵參數和晶胞矩陣是在US 7,501,384中給出: The key parameters and unit cell matrix obtained from the crystallographic study of the crystalline modification II of Becquerel using Siemens' single crystal diffractometer are given in US 7,501,384:
以上所示的該等參數具有以下含義:a,b,c=單位晶胞的棱長;α,β,γ=相應的角度;以及Z=單位晶胞中的分子數。 The parameters shown above have the following meanings: a, b, c = edge length of unit cell; α, β, γ = corresponding angle; and Z = number of molecules in unit cell.
FTIR光譜法可用於記錄IR光譜。 FTIR spectroscopy can be used to record IR spectra.
如果可以提供改進的白克列無水物的結晶變體II之製備方法,特別是適用於在商業規模上應用、具有可重現的高產率的變體II產物之方法,這將是顯著的優勢。較佳的是,該方法操作簡單並且易於控制。 It would be a significant advantage if an improved preparation method of crystalline variant II of becquerel anhydrate can be provided, especially a method suitable for commercial scale application and having a reproducible high yield of variant II product . Preferably, the method is simple to operate and easy to control.
出人意料的是,現在已經發現形成高產率的白克列無水物的結晶變體II是在升高的溫度下發生的。相比之下,較低的溫度導致較佳的是形成白克列無水物的晶體變體I。具體地,當從溶劑系統中沈澱白克列時,出乎意料的是發現在低溫下溶劑系統中白克列的沈澱主要或僅產生了白克列無水物的結晶變體I,然而提高溶劑系統的溫度並且沈澱固體白克列優先產生白克列無水物的結晶II變體。 Surprisingly, it has now been found that the formation of high-yield crystalline variant II of becquerel anhydrate occurs at elevated temperatures. In contrast, the lower temperature leads to the formation of crystal variant I of becquerel anhydrate. Specifically, when precipitating becquerel from the solvent system, it was unexpectedly found that the precipitation of becquerel in the solvent system at a low temperature mainly or only produced the crystalline modification I of the becquerel anhydrous, however, increasing the solvent The temperature of the system and the precipitation of solid becquerel preferentially produce a crystalline II variant of becquerel anhydrate.
圖1是白克列的無水物的結晶變體II之IR光譜;以及圖2是白克列的無水物的結晶變體I之IR光譜。 Fig. 1 is an IR spectrum of crystalline modification II of the anhydrous form of Becquerel; and Fig. 2 is an IR spectrum of crystalline modification I of the anhydrous form of Becquerel.
因此,在第一方面,本發明提供製備白克列無水物的結晶變體II之方法,該方法包括提供在有機溶劑系統中的白克列溶液,將該溶液加熱到升高的溫度,並從該溶液中沈澱固體白克列,其中該升高的溫度足以優先形成白克列無水物的結晶變體II。 Therefore, in a first aspect, the present invention provides a method for preparing crystalline modification II of becquerel anhydrate, the method comprising providing a becquerel solution in an organic solvent system, heating the solution to an elevated temperature, and From the solution, a solid bequerol is precipitated, wherein the elevated temperature is sufficient to preferentially form crystalline modification II of the bequerol anhydrous.
在本發明中,使用升高的溫度來形成白克列無水物之結晶變體II。如上所述,與較低的溫度相比,這種升高的溫度導致優先形成白克列無水物的結晶變體II。 In the present invention, an elevated temperature is used to form crystalline modification II of Becquerel anhydrous. As mentioned above, this increased temperature leads to the preferential formation of crystalline variant II of becquerel anhydrate compared to lower temperatures.
本發明的方法採用白克列起始材料。該白克列起始材料是白克列在有機溶劑系統中的溶液。可以使用任何對於白克列合適的有機溶劑系統來形成本具體實施例所述的白克列起始材料。該溶劑系統可以是單一有機溶劑或兩種或更多種溶劑的混合物。合適的溶劑包括極性有機溶劑和芳香烴。較佳的極性有機溶劑是醇,包括多元醇,例如乙二醇,酮,醚,酯,醯胺及其混合物。 The method of the present invention uses Becquerel starting material. The white clergy starting material is a solution of white clergy in an organic solvent system. Any suitable organic solvent system for becquerel can be used to form the becquerel starting material described in this specific example. The solvent system may be a single organic solvent or a mixture of two or more solvents. Suitable solvents include polar organic solvents and aromatic hydrocarbons. Preferred polar organic solvents are alcohols, including polyhydric alcohols such as ethylene glycol, ketones, ethers, esters, amides, and mixtures thereof.
合適的醇的實例是C1至C8醇,較佳的是C1至C5醇。該醇可以是直鏈或支鏈脂肪醇,更較佳的是乙醇、丙醇和丁醇。該醇可以是脂環族醇,例如環己醇。該溶劑可以包含多元醇,例如乙二醇。合適的乙二醇的實例是單乙二醇和聚乙二醇,較佳的是乙二醇和二甘醇。 Examples of suitable alcohols are C 1 to C 8 alcohols, preferably C 1 to C 5 alcohols. The alcohol may be a linear or branched fatty alcohol, more preferably ethanol, propanol and butanol. The alcohol may be an alicyclic alcohol, such as cyclohexanol. The solvent may contain a polyhydric alcohol, such as ethylene glycol. Examples of suitable ethylene glycols are monoethylene glycol and polyethylene glycol, preferably ethylene glycol and diethylene glycol.
合適的酮的實例是C3至C8酮,較佳的是C3至C6酮,更較佳的是丙酮、丁酮、戊酮和己酮。該等酮可以是直鏈、支鏈或環狀的,例如烷基丙酮和環己酮。 Examples of suitable ketones are C 3 to C 8 ketones, preferably C 3 to C 6 ketones, more preferably acetone, methyl ethyl ketone, amyl ketone and hexanone. The ketones may be linear, branched or cyclic, such as alkyl acetone and cyclohexanone.
合適的醚的實例是C3至C8醚,較佳的是C3至C6醚。該等醚可以是直鏈、支鏈或環狀的,例如二噁烷和四氫呋喃。 Examples of suitable ethers are C 3 to C 8 ethers, preferably C 3 to C 6 ethers. Such ethers may be linear, branched or cyclic, such as dioxane and tetrahydrofuran.
合適的酯的實例是C3至C8酯,較佳的是C3至C6酯,更較佳的是乙酸乙酯和乙酸甲酯。 Examples of suitable esters are C 3 to C 8 esters, preferably C 3 to C 6 esters, more preferably ethyl acetate and methyl acetate.
合適的醯胺的實例是C3至C8醯胺,較佳的是C3至C6醯胺,更較佳的是二甲基甲醯胺。 Examples of suitable amides are C 3 to C 8 amides, preferably C 3 to C 6 amides, and more preferably dimethylformamide.
合適的芳香族溶劑是苯、甲苯和二甲苯。二甲苯是一種較佳的溶劑。 Suitable aromatic solvents are benzene, toluene and xylene. Xylene is a preferred solvent.
合適的溶劑是本領域已知的,並且是可商購的。 Suitable solvents are known in the art and are commercially available.
可以採用溶劑的混合物作為該溶劑系統。例如,該有機溶劑可以包括芳香族溶劑(如苯,二甲苯或甲苯)或環狀烷烴(如環己烯)與一種或多種脂肪族或脂環族醇(如環己醇)、一種或多種酮、一種或多種醚(例如環醚,如四氫呋喃)或一種或多種醯胺的組合。 A mixture of solvents can be used as the solvent system. For example, the organic solvent may include aromatic solvents (such as benzene, xylene or toluene) or cyclic alkanes (such as cyclohexene) and one or more aliphatic or alicyclic alcohols (such as cyclohexanol), one or more A combination of ketones, one or more ethers (eg cyclic ethers, such as tetrahydrofuran) or one or more amides.
本發明的方法中所採用的有機溶劑較佳的是基本上不含水,以確保白克列的無水物的最大生產率。該有機溶劑可以包含最高達按重量計0.4%的水,該水可以由大氣中的溶劑吸收。最佳的是,該有機溶劑也不含水。 The organic solvent used in the method of the present invention is preferably substantially free of water in order to ensure the maximum productivity of the anhydrous product of becquerel. The organic solvent may contain up to 0.4% by weight of water, which can be absorbed by the solvent in the atmosphere. Most preferably, the organic solvent does not contain water.
白克列溶液可以以任何合適的方式形成。例如,可以藉由將白克列的除固體結晶變體II之外的其它形式溶解在有機溶劑系統中來形成該溶液。或者,可在有機溶劑的存在下合成白克列。在有機溶劑中的溶液中合成白克列的合適方法是本領域已知的。US 7,087,239揭露用於製備白克列的合適的合成路徑。 Beacillide solution can be formed in any suitable manner. For example, the solution can be formed by dissolving other forms of Beklee than solid crystalline modification II in an organic solvent system. Alternatively, becoclamide can be synthesized in the presence of an organic solvent. Suitable methods for synthesizing becquerel in solution in organic solvents are known in the art. US 7,087,239 discloses a suitable synthetic route for the preparation of becquerel.
本發明的方法包括從白克列在有機溶劑中的溶液中沈澱固體白克列。將該溶液加熱至升高的溫度。該升高的溫度高於環境溫度或室溫,並且是沈澱優先產生白克列無水物的結晶變體II的溫度。可以採用任何合適的升高的溫度。較佳的是,該升高的溫度低於白克列溶液的沸點。 The method of the present invention includes precipitating solid white clectin from a solution of white clin in an organic solvent. The solution is heated to an elevated temperature. This elevated temperature is higher than the ambient temperature or room temperature, and is the temperature at which precipitation preferentially produces crystalline modification II of becquerel anhydrate. Any suitable elevated temperature can be used. Preferably, the elevated temperature is lower than the boiling point of the Becquerel solution.
合適的升高的溫度可以藉由分析沈澱的白克列材料來確定,特別是確定溫度是否足夠高,以使白克列無水物的變體II沈澱。 A suitable elevated temperature can be determined by analyzing the precipitated Becquerel material, in particular whether the temperature is high enough to precipitate the Becquerel Anhydrous Modification II.
該升高溫度較佳的是至少35℃,更佳的是至少40℃,進一步較佳的是至少45℃。在實驗中,已經發現,加熱至45℃的溫度後,從有機溶劑中的溶液中沈澱白克列產生包含按重量計30%的量的結晶變體II的固體白克列材料。 The elevated temperature is preferably at least 35 ° C, more preferably at least 40 ° C, and still more preferably at least 45 ° C. In experiments, it has been found that after heating to a temperature of 45 ° C., the precipitation of bacilli from a solution in an organic solvent produces a solid bacilli material containing crystalline modification II in an amount of 30% by weight.
更佳的是,在加熱至至少50℃,還更佳的是至少55℃,更較佳的是仍然至少60℃的溫度之後,將白克列從溶液中沈澱出來。在實驗中,已經發現,加熱到65℃的溫度後,從有機溶劑中的溶液中沈澱固體白克列導致形成按重量計100%的白克列無水物的結晶變體II。 More preferably, after heating to a temperature of at least 50 ° C, still more preferably at least 55 ° C, and still more preferably still at least 60 ° C, becoxel is precipitated from the solution. In experiments, it has been found that, after heating to a temperature of 65 ° C., precipitation of solid bequere from a solution in an organic solvent results in the formation of crystalline modification II of 100% by weight of bequere anhydrous.
如上所述,該升高的溫度較佳的是低於有機溶劑和白克列起始材料的溶液之沸點。該升高的溫度也低於白克列無水物的結晶變體II的熔點。 As mentioned above, the elevated temperature is preferably lower than the boiling point of the solution of the organic solvent and the white claire starting material. This elevated temperature is also lower than the melting point of crystalline modification II of Becquerel anhydrous.
該升高的溫度的上限將取決於所採用的特定溶劑或溶劑系統。該升高的溫度較佳的是低於140℃,更佳的是低於130℃,還更佳的是 低於120℃,更較佳的是仍然低於110℃。在較佳的具體實施例中,將固體白克列起始材料加熱至低於100℃,更佳的是低於90℃,還更佳的是低於85℃,更較佳的是仍然低於80℃的升高溫度。 The upper limit of this elevated temperature will depend on the particular solvent or solvent system employed. The elevated temperature is preferably below 140 ° C, more preferably below 130 ° C, still more preferably below 120 ° C, still more preferably still below 110 ° C. In a preferred embodiment, the solid Becquerel starting material is heated below 100 ° C, more preferably below 90 ° C, still more preferably below 85 ° C, still more preferably still low At an elevated temperature of 80 ° C.
較佳的是使用從30℃至130℃範圍內的升高的溫度,更佳的是從35℃至120℃,進一步更佳的是從40℃至110℃,更較佳的是仍然為從45℃至100℃,其中較佳的溫度範圍為從50℃至90℃,更佳的是從55℃至85℃,進一步更佳的是從60℃至80℃。從60℃至70℃的溫度是特別較佳的,其中約65℃的溫度導致形成基本上按重量計100%的白克列無水物的變體II。 It is preferable to use an elevated temperature ranging from 30 ° C to 130 ° C, more preferably from 35 ° C to 120 ° C, even more preferably from 40 ° C to 110 ° C, and still more preferably from 45 ° C to 100 ° C, wherein the preferred temperature range is from 50 ° C to 90 ° C, more preferably from 55 ° C to 85 ° C, and even more preferably from 60 ° C to 80 ° C. A temperature from 60 ° C to 70 ° C is particularly preferred, where a temperature of about 65 ° C results in the formation of a variant II of substantially 100% by weight of white clematis anhydrous.
可使用任何合適的技術來進行從有機溶劑中沈澱出白克列材料。從溶液中沈澱出白克列可以在升高的溫度下進行。例如,可以藉由例如藉由蒸發,例如在減壓下於升高的溫度下除去有機溶劑來進行沈澱。 Any suitable technique can be used to effect the precipitation of the Baccolide material from the organic solvent. Precipitation of Becogli from solution can be carried out at elevated temperature. For example, the precipitation can be carried out by, for example, by evaporation, for example, removing the organic solvent at elevated temperature under reduced pressure.
或者,在將溶液加熱至升高的溫度之後,可在低於該升高的溫度之溫度下進行從溶液中沈澱出白克列。特別地,可以藉由將溶劑中的白克列飽和溶液從升高的溫度冷卻至發生固體白克列沈澱的較低溫度來實現從有機溶劑沈澱出白克列材料。 Alternatively, after heating the solution to an elevated temperature, the precipitation of becoclide from the solution may be performed at a temperature below the elevated temperature. In particular, the precipitation of the white claire material from the organic solvent can be achieved by cooling the saturated solution of white claire in the solvent from an elevated temperature to a lower temperature at which solid white claire precipitation occurs.
作為另外的替代方案,該方法可以採用上述技術的組合,即可以在升高的溫度下開始固體白克列材料的沈澱,並且然後冷卻溶液,例如使另外的固體沈澱。 As a further alternative, the method may use a combination of the above-mentioned techniques, that is, the precipitation of the solid becquerel material may be started at an elevated temperature, and then the solution is cooled, for example to precipitate additional solids.
冷卻可以連續、逐步或以其組合的方式進行。 The cooling can be performed continuously, stepwise, or a combination thereof.
白克列產物的沈澱可以在有機溶劑中在白克列的晶種的存在下進行,較佳的是白克列無水物的結晶變體II的晶種的存在下進行。 The precipitation of the bequere product can be carried out in an organic solvent in the presence of the seed crystals of bequere, preferably in the presence of seed crystals of crystalline modification II of bequere anhydrous.
本發明的方法可以分批進行或以連續方式進行。 The method of the invention can be carried out batchwise or in a continuous manner.
可以使用任何合適的裝置來進行白克列結晶變體II的沈 澱。合適的裝置在本領域中是已知的,並且是可商購的。 The precipitation of Becquerel Crystal Modification II can be carried out using any suitable apparatus. Suitable devices are known in the art and are commercially available.
在另一方面,本發明提供包含藉由上述方法製備的白克列無水物的結晶變體II的殺真菌配製物。 In another aspect, the present invention provides a fungicidal formulation comprising crystalline modification II of becquerel anhydrate prepared by the method described above.
僅為了例示的目的藉由下列具體實例描述本發明的實施方式。 The following specific examples are used to describe the embodiments of the present invention for illustrative purposes only.
在以下實例中,除非另有說明,百分比是重量百分比。 In the following examples, unless otherwise stated, the percentages are percentages by weight.
實例1Example 1
根據以下通用反應方案進行製備白克列:
如下製備在二甲苯中的白克列溶液: Prepare the Bclectin solution in xylene as follows:
將311g的二甲苯中的396g(1.944mol)的2-胺基-4'-氯聯苯裝入到反應容器中,並攪拌該混合物直到得到均勻的溶液。將在233g的二甲苯中的349g(1.984mol)的2-氯-3-菸鹼基氯化物溶液添加到該反應容器中,並允許所得混合物加熱至30℃。 396 g (1.944 mol) of 2-amino-4'-chlorobiphenyl in 311 g of xylene was charged into the reaction vessel, and the mixture was stirred until a homogeneous solution was obtained. A solution of 349 g (1.984 mol) of 2-chloro-3-nicotinyl chloride in 233 g of xylene was added to the reaction vessel, and the resulting mixture was allowed to heat to 30 ° C.
將所得混合物在4至5小時的時間內加熱至95℃的升高的溫度。使用外部洗滌器並使用水和鹼溶液藉由噴霧塔進行吸收除去由反應產生的氯化氫(HCl)。將該反應混合物在相同的升高的溫度下伴隨攪拌進一步保持30分鐘,以除去所有HCL的所有痕跡。此後,將該反應混合物在5至7小時的時間內伴隨緩慢攪拌冷卻至30℃。 The resulting mixture was heated to an elevated temperature of 95 ° C over a period of 4 to 5 hours. Hydrogen chloride (HCl) produced by the reaction was removed by an external scrubber and absorption by a spray tower using water and alkali solution. The reaction mixture was maintained at the same elevated temperature with stirring for a further 30 minutes to remove all traces of all HCL. Thereafter, the reaction mixture was cooled to 30 ° C with slow stirring over a period of 5 to 7 hours.
最後將該溶液冷卻至室溫,導致沈澱出固體白克列材料,藉由過濾除去溶液。藉由在烘箱中真空乾燥從該沈澱物中除去二甲苯痕跡。 Finally, the solution was cooled to room temperature, which resulted in the precipitation of a solid white claire material, and the solution was removed by filtration. Traces of xylene were removed from the precipitate by vacuum drying in an oven.
使用布魯克公司(Bruker)型號Tensor 37光譜儀(記錄波長為550至4000cm-1,具有最高解析度為4cm-1的16次掃描),採用紅外(IR)光譜法分析回收的白克列材料。分析顯示該固體產物是白克列無水物的結晶變體II。 Using Bruker (a Bruker) model Tensor 37 spectrometer (recording wavelength of 550 to 4000cm -1, having the highest resolution of 4cm -1 of 16 scans) using column material Hornbeck infrared (IR) spectrometry recovered. Analysis showed that the solid product was crystalline modification II of becquerel anhydrate.
實例2Example 2
將750g的甲苯在氮氣氣氛下裝入到反應容器中。在室溫下伴隨攪拌添加335g的2-氯菸鹼酸。向該混合物中添加35g的二甲基甲醯胺(DMF),並將所得反應混合物在攪拌下緩慢加熱至40℃。在1小時的時間內添加300g的亞硫醯氯。藉由洗滌除去反應釋放的氯化氫(HCl)和二氧化硫(SO2)。此後,將該反應物料保持在氮氣氛下,並在60℃下保持4至5小時,直至發生酸的完全反應(用HPLC進行監測)。之後,在60℃至75℃下在減壓下除去過量的亞硫醯氯。將所得混合物冷卻至室溫。 750 g of toluene was charged into the reaction vessel under a nitrogen atmosphere. At room temperature, 335 g of 2-chloronicotinic acid was added with stirring. To this mixture, 35 g of dimethylformamide (DMF) was added, and the resulting reaction mixture was slowly heated to 40 ° C with stirring. 300g of sulfenyl chloride was added within 1 hour. Hydrogen chloride (HCl) and sulfur dioxide (SO 2 ) released by the reaction are removed by washing. Thereafter, the reaction mass was kept under a nitrogen atmosphere and at 60 ° C. for 4 to 5 hours until a complete reaction of the acid occurred (monitored by HPLC). Thereafter, excess sulfenyl chloride is removed under reduced pressure at 60 ° C to 75 ° C. The resulting mixture was cooled to room temperature.
將冷卻的混合物在攪拌下用500g的甲苯和200g的三乙胺(TEA)稀釋。在45℃下,在30至45分鐘的時間內向此均勻混合物中添加400g的4'-氯聯苯-2-胺,並且再攪拌該混合物4至5小時使反應完成。藉由添加水並再攪拌2至3小時淬滅該混合物。 The cooled mixture was diluted with 500 g of toluene and 200 g of triethylamine (TEA) with stirring. At 45 ° C., 400 g of 4′-chlorobiphenyl-2-amine was added to this homogeneous mixture over a period of 30 to 45 minutes, and the mixture was further stirred for 4 to 5 hours to complete the reaction. The mixture was quenched by adding water and stirring for an additional 2 to 3 hours.
將有機層分離並保持在60℃之升高的溫度。過濾該混合物以除去不溶性雜質。在緩慢攪拌下將該混合物最終冷卻至10℃至15℃。藉由過濾並乾燥分離固體,得到450至480g的白克列。 The organic layer was separated and maintained at an elevated temperature of 60 ° C. The mixture was filtered to remove insoluble impurities. The mixture was finally cooled to 10 to 15 ° C with slow stirring. The solid was separated by filtration and dried to obtain 450 to 480 g of white clematis.
如實例1中藉由IR光譜分析該固體,這顯示該固體產物是白克列無水物的結晶變體II。 The solid was analyzed by IR spectroscopy as in Example 1, which showed that the solid product was crystalline modification II of Becquerel anhydrous.
實例3Example 3
將於622g的二甲苯中的792g(3.888mol)的2-胺基-4'-氯聯苯裝入到反應容器中,並攪拌該混合物直到得到均勻的溶液。將在466g的二甲苯中的698g(3.968mol)的2-氯-3-菸鹼基氯化物溶液添加到該反應容器中,並允許所得混合物加熱至30℃的溫度。 792 g (3.888 mol) of 2-amino-4′-chlorobiphenyl in 622 g of xylene was charged into the reaction vessel, and the mixture was stirred until a homogeneous solution was obtained. A solution of 698 g (3.968 mol) of 2-chloro-3-nicotinyl chloride in 466 g of xylene was added to the reaction vessel, and the resulting mixture was allowed to heat to a temperature of 30 ° C.
將所得混合物在4至5小時的時間內加熱至95℃之升高的溫度。使用外部洗滌器並使用水和鹼溶液藉由噴霧塔進行吸收除去由反應產生的氯化氫(HCl)。將該反應混合物在相同的升高的溫度下伴隨攪拌進一步保持從2至3小時之時間,以除去所有HCl的所有痕跡。 The resulting mixture was heated to an elevated temperature of 95 ° C over a period of 4 to 5 hours. Hydrogen chloride (HCl) produced by the reaction was removed by an external scrubber and absorption by a spray tower using water and alkali solution. The reaction mixture was further maintained at the same elevated temperature with stirring for a period of from 2 to 3 hours to remove all traces of all HCl.
將所得混合物用白克列無水物的結晶變體II的晶種接種,導致固體材料的沈澱,藉由過濾收集該固體材料。藉由在烘箱中真空乾燥從該沈澱物中除去二甲苯痕跡。 The resulting mixture was seeded with seed crystals of Crystalline Modification II of Becquerel Anhydrous, resulting in precipitation of a solid material, which was collected by filtration. Traces of xylene were removed from the precipitate by vacuum drying in an oven.
使用布魯克公司(Bruker)型號Tensor 37光譜儀(記錄波長為550至4000cm-1,具有最高解析度為4cm-1的16次掃描),採用紅外(IR)光譜法分析收集的固體材料。分析顯示該固體產物是白克列無水物的結晶變體II。 Using Bruker (a Bruker) model Tensor 37 spectrometer (recording wavelength of 550 to 4000cm -1, having the highest resolution of 4cm -1 16 scans), the solid material employed infrared (IR) spectrometry collected. Analysis showed that the solid product was crystalline modification II of becquerel anhydrate.
實例4Example 4
按照實例2中描述的步驟製備375g的氯菸鹼酸的羰基中間體,並與400g的4'-氯聯苯-2-胺反應,得到粗製的白克列產物。將該產物用四氫呋喃(THF)反復洗滌,並用850g的異丙醇稀釋。將所得溶液加熱至60℃並在該溫度下保持2至3小時。 The carbonyl intermediate of chloronicotinic acid was prepared according to the procedure described in Example 2 and reacted with 400 g of 4'-chlorobiphenyl-2-amine to obtain a crude becquerel product. The product was repeatedly washed with tetrahydrofuran (THF) and diluted with 850 g of isopropanol. The resulting solution was heated to 60 ° C and maintained at this temperature for 2 to 3 hours.
冷卻所得混合物以獲得固體沈澱物。藉由過濾和乾燥分離該固體。 The resulting mixture was cooled to obtain a solid precipitate. The solid was isolated by filtration and drying.
如實例1中藉由IR光譜分析該固體,其顯示該固體產物是白克列無水物的結晶變體II。 The solid was analyzed by IR spectroscopy as in Example 1, which showed that the solid product was crystalline modification II of Becquerel anhydrous.
為了研究溫度對該方法中得到的固體白克列材料的影響,重複實例1的步驟,其中在冷卻之前從保持在不同的升高的溫度範圍內的二甲苯溶液中沈澱出固體白克列。 In order to study the effect of temperature on the solid white clematis material obtained in the process, the procedure of Example 1 was repeated, in which solid white clematis was precipitated from a xylene solution maintained in a different elevated temperature range before cooling.
結果總結在下表中。 The results are summarized in the table below.
從上表總結的結果可以看出,從有機溶劑中沈澱的白克列無水物的形式取決於從其中進行沈澱的白克列溶液的溫度。具體地,從加熱至65℃的溫度的二甲苯的沈澱產生了100%白克列無水物的結晶變體II。相比之下,從加熱到剛好30℃的二甲苯溶液的沈澱僅產生了10%至20%的白克列無水物的結晶變體II,在該溫度下主要形成了白克列無水物的結晶變體I。 From the results summarized in the above table, it can be seen that the form of the white clergy anhydrous precipitated from the organic solvent depends on the temperature of the white clergy solution precipitated therefrom. Specifically, the precipitation of xylene heated to a temperature of 65 ° C. produced a crystalline modification II of 100% becquerel anhydrous. In contrast, the precipitation of the xylene solution heated to just 30 ° C produced only 10% to 20% of the crystalline variant II of the white kleeline anhydrate, at which the main form of the white kleeline anhydrate Crystalline modification I.
Claims (27)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1613462.9 | 2016-08-04 | ||
??1613462.9 | 2016-08-04 | ||
GB1613462.9A GB2552699B (en) | 2016-08-04 | 2016-08-04 | Process for preparing boscalid |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201808904A true TW201808904A (en) | 2018-03-16 |
TWI733869B TWI733869B (en) | 2021-07-21 |
Family
ID=60940414
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106126004A TWI733869B (en) | 2016-08-04 | 2017-08-02 | Process for preparing boscalid |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN109476603A (en) |
GB (1) | GB2552699B (en) |
TW (1) | TWI733869B (en) |
WO (1) | WO2018024145A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023062649A1 (en) * | 2021-10-14 | 2023-04-20 | Natco Pharma Limited | An improved process for the preparation of anhydrous crystalline form-i of boscalid |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087239B2 (en) * | 2001-09-25 | 2006-08-08 | Basf Aktiengesellschaft | Crystalline hydrates of anilide derivatives |
EA007106B1 (en) * | 2001-11-02 | 2006-06-30 | Басф Акциенгезельшафт | Method for producing 2-halogen-ptridine-carboxylic acid amines |
DE10307751A1 (en) * | 2003-02-14 | 2004-08-26 | Basf Ag | New monoclinic boscalide crystal modification with defined melting point useful as herbicide |
CN103073489A (en) * | 2013-02-06 | 2013-05-01 | 利民化工股份有限公司 | Preparation method of Boscalid |
CN103980192B (en) * | 2014-01-20 | 2016-02-17 | 泰州百力化学股份有限公司 | A kind of method of selectivity synthesis different crystal forms boscalid amine |
CN105541709A (en) * | 2016-02-25 | 2016-05-04 | 尚振华 | Method for preparing boscalid |
-
2016
- 2016-08-04 GB GB1613462.9A patent/GB2552699B/en not_active Expired - Fee Related
-
2017
- 2017-07-27 WO PCT/CN2017/094624 patent/WO2018024145A1/en active Application Filing
- 2017-07-27 CN CN201780044954.4A patent/CN109476603A/en active Pending
- 2017-08-02 TW TW106126004A patent/TWI733869B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN109476603A (en) | 2019-03-15 |
GB2552699B (en) | 2021-03-10 |
TWI733869B (en) | 2021-07-21 |
WO2018024145A1 (en) | 2018-02-08 |
GB2552699A (en) | 2018-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5305248B2 (en) | New nateglinide crystals | |
KR102266680B1 (en) | Polymorphic Forms of Belinostet and Methods of Making It | |
JP6269508B2 (en) | Process for producing purified amine compound | |
US10364225B2 (en) | Process for preparing boscalid | |
TWI756173B (en) | Process for preparing boscalid | |
TWI733869B (en) | Process for preparing boscalid | |
KR20100045985A (en) | Process for producing toluidine compound | |
TWI750119B (en) | Process for drying polymorph i of anhydrate of boscalid | |
TWI364282B (en) | Cefcapene pivoxil methanesulfonic acid salt | |
WO2017081014A1 (en) | Process for the preparation of eltrombopag olamine | |
ES2566376T3 (en) | Process to prepare 1,2-bencisothiazolin-3-one | |
AU2013368947A1 (en) | Process for preparing amorphous Cabazitaxel | |
TWI777967B (en) | Process for preparing boscalid | |
JP7519376B2 (en) | Method for producing rosuvastatin calcium salt | |
WO2018024146A1 (en) | Process for preparation of boscalid | |
TW202237594A (en) | Process for the production of 5-(4-((2s,5s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1h-1,2,4-triazol-3-amine | |
KR20160029062A (en) | 1,1-bis(4-(2-hydroxyethoxy)phenyl)-3,3,5-trimethylcyclohexane crystalline body and production method therefor | |
CN115703745A (en) | Preparation method of enzalutamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |